Oraya Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.orayainc.com
Clinical Trials
6
Active:0
Completed:1
Trial Phases
3 Phases
Phase 1:1
Phase 2:2
Not Applicable:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Not Applicable
3 (50.0%)Phase 2
2 (33.3%)Phase 1
1 (16.7%)Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
Not Applicable
- Conditions
- Retinal Pigment Epithelial Detachment With VascularizationAge Related Macular Degeneration
- Interventions
- Radiation: Iray
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01521819
- Locations
- 🇮🇹
Università Vita-Salute Istituto Scientifico San Raffaele, Milano, Italy
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Phase 2
- Conditions
- Age-Related Macular DegenerationWet Macular DegenerationMacular DegenerationEye DiseasesRetinal Diseases
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01521065
- Locations
- 🇬🇧
Manchester Royal Eye Hospital, Manchester, United Kingdom
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
Not Applicable
- Conditions
- Polypoidal Chorodial VasculopathyAge Related Macular Degeneration
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01516294
- Locations
- 🇮🇹
Università Vita-Salute Istituto Scientifico San Raffaele, Milano, Italy
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
Not Applicable
Withdrawn
- Conditions
- Wet Age-related Macular DegenerationAge-related Macular DegenerationWet AMDMacular DegenerationAMD
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Registration Number
- NCT01339949
- Locations
- 🇮🇹
Università Vita-Salute Istituto Scientifico San Raffaele, Milan, Italy
🇬🇧King's College Hospital, London, United Kingdom
🇬🇧Manchester Royal Eye Hospital, Manchester, United Kingdom
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Phase 1
- Conditions
- Age-Related Macular DegenerationWet Age-Related Macular DegenerationMacular DegenerationEye DiseasesRetinal Diseases
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01217762
- Locations
- 🇲🇽
Asociación Para Evitar la Ceguera en México, I.A.P., Mexico Distrito Federal, Delegación Coyoacán, Mexico
- Prev
- 1
- 2
- Next
News
No news found